Abstract
Cystic fibrosis (CF) is the most common life-threatening genetic condition in the Caucasian population. Since the complete pathologic description of the disease in 1938, tremendous progress has been made in identifying its genetic basis, the pathophysiology of CF lung disease, and the development of new therapies. This issue of CRAI will review several areas of progress in our understanding and treatment of CF.
Similar content being viewed by others
References
Andersen D (1938) Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56:344–399
Davis PB (2001) Cystic fibrosis. Pediatr Rev 22:257–264
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073
Davis PB (2006) Cystic fibrosis since 1938. Am J Respir Crit Care Med 173:475–482
Cantin A (1995) Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med 151:939–941
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075–1082
Ferkol T, Rosenfeld M, Milla CE (2006) Cystic fibrosis pulmonary exacerbations. J Pediatr 148:259–264
Liou TG, Adler FR, FitzSimmons SC, Cahill BC, Hibbs JR, Marshall BC (2001) Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 153:345–352
Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB et al (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354:229–240
Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ et al (2001) A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139:813–820
Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J et al (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340:23–30
Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA et al (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749–1756
Cystic Fibrosis Foundation Patient Registry (2006) Cystic Fibrosis Foundation, Bethesda, MD
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ren, C.L. Cystic Fibrosis: Evolution from a Fatal Disease of Infancy with a Clear Phenotype to a Chronic Disease of Adulthood with Diverse Manifestations. Clinic Rev Allerg Immunol 35, 97–99 (2008). https://doi.org/10.1007/s12016-008-8077-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-008-8077-y